Polymorphisms of the tissue factor pathway inhibitor gene and the risk of restenosis after coronary angioplasty

Blood Coagulation and Fibrinolysis

Volumn 12, Issue 4, 2001, Pages 317-323

  Moatti, D ^a   Meirhaeghe, A ^b   Ollivier, V ^a   Bauters, C ^b,c   Amouyel, P ^b,c   De Prost, D ^a,d  

^a INSERM   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d HÔPITAL LOUIS MOURIER   (France)

Author keywords

Angioplasty; Polymorphisms; Restenosis; Tissue factor pathway inhibitor

Indexed keywords

ENOXAPARIN; RESTRICTION ENDONUCLEASE; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD VESSEL DIAMETER; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY STENT; EXON; FEMALE; HUMAN; INTRON; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROMOTER REGION; RESTENOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK;

EID: 0034974063     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200106000-00013     Document Type: Article

References (21)

1. Incidence of restenosis after succesful angioplasty: A time-related phenomenom
2. Tissue factor induces migration of cultured aortic smooth muscle cells
3. Mitogenic activity of blood components I: Thrombin and prothrombin
4. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells
5. Tissue factor pathway inhibitor and the revised theory of coagulation
6. Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIIa complex
7. Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells
8. Influence of blockade at specific levels of the coagulation cascade on restenosis ina rabbit atherosclerotic femoral artery injury model
9. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs
10. A new T-287C polymorphism in the 5′ regulatory region of the tissue factor pathway inhibitor gene. Association study of the T-287C and C-399T polymorphisms with coronary artery disease and plasma TFPI levels
11. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: Impact of the V264M substitution on plasma levels of TFPI
12. Intron-Exon organization of the human gene coding for the lipoprotein-associated coagulation inhibitor - The factor-Xa dependent inhibitor of the extrinsic pathway of coagulation
13. Relation between the deletion polymorphism of the angiotensin-converting enzyme gene and late luminal narrowing after coronary angioplasty
14. D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting
15. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor
16. No link between the TFPI V264M mutation and venous thromboembolic disease
17. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI)
18. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina
19. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients
20. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture
21. Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus